Analytical Method Development and Validation for Simultaneous Estimation of Olmesartan Medoxomil and Cilnidipine in their Combined Pharmaceutical Dosage form by RP-HPLC Method

Abstract

RP-HPLC method was developed for the simultaneous estimation of Olmesartan Medoxmil and Cilnidipine in pharmaceutical dosage form. The separation was achieved Hypersil C18 (250 x 4.6 mm, 5 mm) columnwith Acetonitritle:Phosphate buffer pH 3.6 (70:30 %v/v). Flow rate was maintained at 1.0 ml/ min and UV detection was carried at 270 nm. Retention time for Olmesartan Medoxomil and Cilnidipine was found to be 4.14 min and 7.79 min respectively. The method has been validated for linearity, accuracy and precision. Linearity for Olmesartan Medoxomil and Cilnidipine were in the range of 40 - 200 µg/ml and 10 - 50 µg/ml respectively. The percentage recoveries obtained for Olmesartan Medoxomil and Cilnidipine were found to be in range of 99.96- 100.23 and 98.99-100.03 respectively. The developed method was validated as per ICH guidelines. Developed method was found to be accurate, precise, selective and rapid for simultaneous estimation of Olmesartan Medoxomil and Cilnidipine  in pharmaceutical dosage form.